Anlon Healthcare IPO
GMP, Subscription, Price, Dates & Financial Details
Pharmaceutical & Drugs
Incorporated in 2013, Anlon Healthcare Limited is a specialty chemical manufacturing company focused on the production of high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs). These products are critical components used in the formulation of medicines,…
Open Date
Tue, 26 Aug 2025
Close Date
Fri, 29 Aug 2025
Price Band
₹ 86 – 91
Lot Size
164
Issue Size
₹ 121.03 Cr
Minimum Investment
₹ 14,924 (164 Shares)
Grey Market Premium Analysis
Day Wise GMP→Unofficial premium quoted in the grey market, tracked daily against the price band cap.
Grey market trading is unregulated. GMP figures are indicative only and should not be the sole basis for investment decisions - treat as a sentiment indicator, not a guarantee.
IPO Details
Anlon Healthcare IPO has successfully completed its IPO process and is now listed on the NSE and BSE. According to the Red Herring Prospectus (RHP), the IPO was a book-built issue with a total issue size of ₹121.03 Crore, comprising a fresh issue of 1.33 Crore equity shares aggregating to ₹121.03 Crore.
The Anlon Healthcare IPO remained open for subscription from August 26, 2025, to August 29, 2025. The basis of allotment was finalized on September 01, 2025, and the company's shares were listed on the NSE and BSE on September 03, 2025.
The company had fixed the price band at ₹86 to ₹91 per share, with a lot size of 164 shares. Retail investors were required to make a minimum investment of ₹14,924 (based on the upper price band) to apply for one lot.
KFin Technologies Limited served as the registrar to the issue. Interactive Financial Services Ltd acted as the Book Running Lead Managers (BRLMs) to the issue.
With the successful completion of the IPO process, Anlon Healthcare Ltd is now a publicly listed company on the NSE and BSE. Investors can track the company's share price, trading performance, financial results, and corporate announcements through the stock exchanges.
Anlon Healthcare IPO Timeline (Tentative)
- IPO Open Date
- Tue, 26 Aug 25
- IPO Close Date
- Fri, 29 Aug 25
- Basis of Allotment
- Mon, 01 Sep 25
- Initiation of Refunds
- Tue, 02 Sep 25
- Credit of Shares to Demat
- Tue, 02 Sep 25
- Listing Date
- Wed, 03 Sep 25 — NSE & BSE
Open Date
26 August 2025
Close Date
29 August 2025
Basis Of Allotment
01 September 2025
Listing Date
03 September 2025
IPO Subscription
Check Live Subscription →The Anlon Healthcare IPO has received bids for 9,47,62,808 shares against 1,33,00,000 shares offered, resulting in an overall subscription of 7.13x. the NII category is subscribed 10.61x, Retail Investors 47.3x, and QIBs 1.07x. Within the NII category, BNII is subscribed 7.56x, while SNII is subscribed 16.69x.
QIB
1.07x
NII
10.61x
BNII
7.56x
SNII
16.69x
RII
47.3x
Total
7.13x
IPO Reservations
The Retail Individual Investor (RII) category has the highest allocation with 13,30,000 shares, representing 10% of the total issue. Qualified Institutional Buyers (QIBs) are allocated 99,75,000 shares (75%), while Non-Institutional Investors (NIIs) receive 19,95,000 shares (15%).
| Category | Shares Offered | Shares Offered % |
|---|---|---|
| Qualified Institutions | 9,975,000 | 75% |
| Non-Institutional | 1,995,000 | 15% |
| BNII | 1,330,000 | 10% |
| SNII | 665,000 | 5% |
| Retail Investors | 1,330,000 | 10% |
| Total | 13,300,000 | 100% |
Financials Details(₹ in Crores)
| Particular | 31 Jan 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 181.3 | 128 | 111.55 |
| Revenue | 120.46 | 66.69 | 113.12 |
| Profit After Tax | 20.52 | 9.66 | 5.82 |
| Net Worth | 80.42 | 21.03 | 7.37 |
| Reserve & Surplus | 40.57 | 5.03 | -4.63 |
| Total Borrowings | 58.35 | 74.56 | 66.39 |
Financials Performance
Performance Indicators
EPS Pre
Earnings per share before the IPO.
P/E Pre
IPO Offer Price ÷ EPS Pre.
EPS Post
Expected earnings per share after the IPO..
P/E (Post Issue)
IPO Offer Price ÷ EPS Post.
Anlon Healthcare Ltd KPI Information
| Particular | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE % | 40.45 | 67.99 | 130.37 |
| ROCE % | 21.93 | 16.29 | 17.16 |
| Debt / Equity | 0.73 | 3.55 | 9 |
| RoNW % | 25.21 | 45.92 | 78.92 |
| Pat Margin % | 17.06 | 14.5 | 5.16 |
Peers Comparison
| Company | Face Value | PE Ratio | EPS Basic | EPS Diluted | RoNW | Net Assets |
|---|---|---|---|---|---|---|
| Anlon Healthcare Ltd | 10 | 0.00 | 6.38 | 6.38 | 25.51 | 20.18 |
| Kronox Lab Sciences Ltd | 10 | 26.18 | 6.91 | 6.91 | 28.26 | 24.28 |
| Acutaas Chemicals Ltd | 5 | 58.47 | 19.81 | 19.81 | 12.15 | 161.24 |
| Supriya Lifeciences Ltd | 2 | 29.27 | 23.35 | 23.35 | 18.86 | 123.85 |
About Anlon Healthcare Ltd
Incorporated in 2013, Anlon Healthcare Limited is a specialty chemical manufacturing company focused on the production of high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs). These products are critical components used in the formulation of medicines, nutraceuticals, personal care items, and veterinary products.
Core Capabilities
Anlon manufactures pharmaceutical intermediates and APIs in compliance with global pharmacopeia standards, including IP, BP, EP, JP, and USP. The company has also expanded into custom synthesis of complex chemicals, offering solutions that exceed purity requirements and meet stringent customer specifications.
The company's API portfolio includes products approved by major regulatory bodies such as:
- ANVISA (Brazil)
- NMPA (China)
- PMDA (Japan)
Notably, Anlon is among the few Indian manufacturers of Loxoprofen Sodium Dihydrate, a widely used anti-inflammatory API.
Product Portfolio (As of January 31, 2025)
Anlon’s portfolio spans 142 products across various stages of development:
- 65 Commercialized
- 28 At pilot stage
- 49 In laboratory testing
Breakdown by category:
- 22 Pharmaceutical Intermediates
- 18 Active Pharmaceutical Ingredients (APIs)
- 20 Nutraceutical APIs
- 3 Personal Care Intermediates
- 2 Veterinary APIs
The company has filed 21 Drug Master Files (DMFs) across global jurisdictions and is actively pursuing additional filings, including for Ketoprofen and Dexketoprofen Trometamol.
Manufacturing and Quality
With a strong focus on quality, safety, and environmental responsibility, Anlon ensures all products undergo rigorous testing, analysis, and process validation. Supported by four in-house laboratories, the company's quality systems are managed by a 34-member team—including 24 science graduates—dedicated to R&D, QC, and QA.
Workforce
As of January 31, 2025, Anlon employed:
- 105 full-time employees (excluding trainees)
- 8 contract workers
Key Products
- Pharma Intermediates: Examples include Cyanoethylbenzoic Acid, Ketonitrile, and Methyldesloratadine, used as starting materials or advanced intermediates in API manufacturing.
- Active Pharmaceutical Ingredients (APIs): Used in tablets, capsules, syrups, ointments, and other formulations across human and animal health, nutraceuticals, and personal care.
Global Reach
Anlon serves clients in over 15 countries, including Italy, Germany, Japan, and Brazil.
Competitive Strengths
- Diverse and scalable product portfolio
- Strong promoter backing and experienced management
- High entry barriers due to long customer approval cycles
- In-house capabilities for testing, quality control, and assurance
- Commitment to quality, environment, health, and safety standards
Anlon Healthcare IPO Promoters
- Punitkumar R. rasadia
- Meet Atulkumar Vachhani
- Mamata punitkumar Rasadia
Promoters Holding
Holding Pre Issue
70.26%
Holding Post Issue
52.68%
Anlon Healthcare IPO Objective
The Company Anlon Healthcare IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
- Funding capital expenditure requirements for Proposed Expansion
- Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company
- Funding the working capital requirements of the Company
- General corporate purposes
Anlon Healthcare Ltd Address / Contact Details
Anlon Healthcare Limited
101/102, Silvercoin Complex,
Opp.Crystal Mall,
Kalawad Road,
Rajkot, Gujarat, 360005
Phone: +91 281 2562538
Email: cs@anloncro.com
Website: http://www.anlon.in/
IPO Snapshot
Anlon Healthcare IPO Lot Size
The Anlon Healthcare IPO has a lot size of 164 shares. Retail investors require a minimum investment of ₹14,924 by applying for 1 lot (164 shares). The maximum application allowed for the retail category is 13 lots (2,132 shares), requiring an investment of ₹1,94,012.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 164 | 14,924.00 |
| Retail (Max) | 13 | 2,132 | 194,012.00 |
| S-HNI (Min) | 14 | 2,296 | 208,936.00 |
| S-HNI (Max) | 67 | 10,988 | 999,908.00 |
| B-HNI (Min) | 68 | 11,152 | 1,014,832.00 |
Issue Reservation
- QIB — 75%
- NII — 15%
- RII — 10%
Book Running Lead Managers
- Interactive Financial Services Ltd
IPO Documents & Links
Explore More IPOs
Currently Open
Coming Up Next
Disclaimer: This data is for informational purposes only and does not constitute investment advice.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Anlon Healthcare IPO?
Anlon Healthcare IPO is a Book-building IPO with a total issue size of ₹121.03 crore. The Anlon Healthcare IPO price band is ₹86 to 91 per share. The Anlon Healthcare IPO subscription opens on Tue, Aug 26, 2025, and closes on Fri, Aug 29, 2025. The Anlon Healthcare IPO will be listed on the BSE,NSE. KFin Technologies Limited is the registrar for the Anlon Healthcare IPO.
When will the Anlon Healthcare IPO open for subscription?
The Anlon Healthcare IPO opens on Tue, Aug 26, 2025 and closes on Fri, Aug 29, 2025
What is Anlon Healthcare IPO Price Band?
Anlon Healthcare IPO Price Band is ₹86 to 91 per share.
What is Anlon Healthcare IPO Lot Size?
Anlon Healthcare IPO lot size is 164 shares, Retail investors need a minimum investment of ₹14924 based on the upper price band
What is the minimum investment for Anlon Healthcare IPO?
The minimum investment for Anlon Healthcare IPO is ₹14924, based on one lot of 164 shares at the upper price band of ₹91 per share.
How to apply for Anlon Healthcare IPO?
Investors can apply for the Anlon Healthcare IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Fri, Aug 29, 2025. The application amount remains blocked until the Anlon Healthcare IPO allotment is finalized.
What is Anlon Healthcare IPO Issue Size?
Anlon Healthcare IPO issue size is ₹121.03 crores.
What is the Anlon Healthcare IPO Allotment Date?
Anlon Healthcare IPO allotment date is Mon, Sep 1, 2025.
Who is the Anlon Healthcare IPO Registrar?
The registrar for Anlon Healthcare IPO is KFin Technologies Limited. Investors can go to KFin Technologies Limited website to check Anlon Healthcare IPO allotment status, refund processing, and other IPO-related information.
What is the Anlon Healthcare IPO GMP?
The Anlon Healthcare IPO GMP (Grey Market Premium) is ₹1 as of Wed, Sep 3, 2025. Based on the upper price band of ₹91 per share, the estimated Anlon Healthcare IPO listing price is ₹92, indicating a potential listing gain of approximately 1.10% over the issue price.
Who is the Anlon Healthcare IPO Lead Manager?
The book-running lead managers (BRLMs) for the Anlon Healthcare IPO are Interactive Financial Services Ltd. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Anlon Healthcare IPO Red Herring Prospectus (RHP).